Drug toxicity is the major cuase of current drug R&D failures and market withdrawl of launched drugs, and rescuing failed drugs is now emerging as a primary concern of pharmaceutical industry.
To rescue failed drugs effectively, understanding the molecular insights of the drug toxicity is highly required.
Prevoius reports have shown the strong evidence that single nucleotide polymorphism (SNP) variations of toxicity targets affect the drug toxicity in each patient,
providing the rationale for toxicity target SNP-based drug rescuing for personalized therapy by identifying individuals at elevated risk for drug toxicity and excluding them from the treatment.
For this SNP-based drug rescuing approach, precise identification of toxicity targets of failed drugs is premised and genome-wide drug on/off-target screening system is highly required for the purpose.
In this regard, Bioneer's-exclusive genome-wide drug on/off-target screening system (GPScreen™ HT) that combines NGS technology and GPScreen™ enables the clear-cut identification of the
drug toxicity(off)-targets which are posssibly involved in in-vivo toxicity of drug candidates, thereby providing the rationale for toxicity target SNP-based drug rescue for personalized therapy.
Therefore, GPScreen™ technology is a powerful tool for genome-wide drug toxicity target identification and can be applied effectively as an innovative system for drug rescue of many failed drugs of pharmaceutical companies.
Process of Drug Rescue with GPScreen™
As descrived above, the precise identification of toxicity targets of failed drugs with GPScreen will enhance the drug rescue of them very effectively. The detailed process of drug rescue with GPScreen™ is as below.
I. Flow Chart of drug rescue with GPScreen™
II. Toxicity Target Discovery of failed drugs with GPScreen™
Below is an example of toxicity target identification of a failed drug with GPScreen™ for drug rescue.
In this study, using a failed drug which was withdrawn from market due to cardiotoxicity problem, we performed GPScreen and found some promising toxicity targets which are possibly involved in in-vivo cardiotoxicity.